Overcoming the age barrier in hematopoietic stem cell transplantation: Progress, but still a long way to go

JAMA

Volumn 306, Issue 17, 2011, Pages 1918-1920

  Mineishi, Shin ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; CALCINEURIN INHIBITOR; NARCOTIC AGENT; STEROID;

AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL DECISION MAKING; DRUG MEGADOSE; DRUG TOLERANCE; EDITORIAL; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; RISK FACTOR; TREATMENT INDICATION; WHOLE BODY RADIATION;

EID: 80355148397     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1612     Document Type: Editorial

References (15)

1. Thomas ED. A history of haemopoietic cell transplantation. Br J Haematol. 1999;105(2):330-339. (Pubitemid 29232151)
2. Storb R. Allogeneic hematopoietic stem cell transplantation: yesterday, today, and tomorrow. Exp Hematol. 2003;31(1):1-10. (Pubitemid 36110525)
3. Giralt S, Estey E, AlbitarM, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versusleukemia without myeloablative therapy. Blood. 1997;89(12):4531-4536. (Pubitemid 27260263)
4. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756-763. (Pubitemid 28078275)
5. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390-3400.
6. Sorror ML, Sandmaier BM, Storer BE, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306(17):1874-1883.
7. CDC WONDER Database. Cancer incidence 1999-2008. http://wonder.cdc.gov/ wonder/help/cancernpcr-v2008.html/. Accessed October 17, 2011.
8. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481-3485.
9. US Department of Commerce, US Census Bureau. The next four decades: the older population in United States 2010 to 2050. http://www.census.gov/prod/ 2010pubs/p25-1138.pdf. May 2010. Accessed October 17, 2011.
10. Estey E, de Lima M, Tibes R, et al. Prospective feasibility analysis of reducedintensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109(4):1395-1400. (Pubitemid 46239569)
11. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-2919. (Pubitemid 41510773)
12. Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110(13):4606-4613. (Pubitemid 351377830)
13. Smith AR, Majhail NS, MacMillan ML, et al. Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients. Blood. 2011;117(9):2728-2734.
14. Majhail NS, Brunstein CG, McAvoy S, et al. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? a validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant. 2008;14(9):985-992.
15. Sperr WR, Wimazal F, Kundi M, et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol. 2010;21(1):114-119.